GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
GH Research PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$18.28+0.13 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | -20.3% | |
| Current ratio | – | 24.03 | 34.13 | |
| Interest coverage | – | – | -131.1× | |
| Diluted shares | – | 28M | 61M |
Where the cash went
Fiscal 2021 to 2025, five years combined
GH Research generated $160.66M from operations and spent $441.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$160.66M
Used
$441.00K
Capital expenditure$441.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$48.26M
- Cash generatingOperating cash flow above zero-$43.55M
- Return on assets improvedROA up on the prior year-17.2% → -25.6%
- Earnings backed by cashOperating cash flow above net income-$43.55M vs -$48.26M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose17.23 → 34.13
- No dilutionShare count did not rise52M → 61M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –